-
Product Name
SLC22A18 antibody
- Documents
-
Description
SLC22A18 Rabbit Polyclonal antibody. Positive WB detected in mouse brain tissue, COLO 320 cells. Positive IP detected in mouse brain tissue. Observed molecular weight by Western-blot: 40-50kd
-
Tested applications
ELISA, WB, IP
-
Species reactivity
Human,Mouse,Rat; other species not tested.
-
Alternative names
BWR1A antibody; BWSCR1A antibody; DKFZp667A184 antibody; HET antibody; IMPT1 antibody; ITM antibody; ORCTL 2 antibody; ORCTL2 antibody; p45 BWR1A antibody; SLC22A18 antibody; SLC22A1L antibody; TSSC5 antibody
-
Isotype
Rabbit IgG
-
Preparation
This antibody was obtained by immunization of SLC22A18 recombinant protein (Accession Number: XM_047427033). Purification method: Antigen affinity purified.
-
Clonality
Polyclonal
-
Formulation
PBS with 0.1% sodium azide and 50% glycerol pH 7.3.
-
Storage instructions
Store at -20℃. DO NOT ALIQUOT
-
Applications
Recommended Dilution:
WB: 1:1000-1:10000
IP: 1:200-1:2000
-
Validations
mouse brain tissue were subjected to SDS PAGE followed by western blot with Catalog No:115314(SLC22A18 antibody) at dilution of 1:1000
IP Result of anti-SLC22A18 (IP:Catalog No:115314, 4ug; Detection:Catalog No:115314 1:600) with mouse brain tissue lysate 4000ug.
-
Background
SLC22A18 is a member of the family of polyspecific organic-cation transporters that localize at the apical membrane surface of renal proximal tubules. SLC22A18 is expressed at high levels in the kidney, liver, colon and in fetal renal proximal tubules and present at lower levels in heart, brain and lung. Defects in SLC22A18 are associated with breast and lung cancer and are the cause of rhabdomyosarcoma type 1, a malignant tumor derived from striated muscle. More recently, SLC22A18 has been shown to functions as a tumor suppressor in glioma and represents a candidate biomarker for long-term survival in this disease.
-
References
- Zhang B, Liu T, Wu T, Wang Z, Rao Z, Gao J. microRNA-137 functions as a tumor suppressor in human non-small cell lung cancer by targeting SLC22A18. International journal of biological macromolecules. 74:111-8. 2015.
- He H, Xu C, Zhao Z, Qin X, Xu H, Zhang H. Low expression of SLC22A18 predicts poor survival outcome in patients with breast cancer after surgery. Cancer epidemiology. 35(3):279-85. 2011.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"